ArticleBioactive materials2026
Injectable chondroitin sulfate-glycosylated decellularized extracellular matrix microgels activate Wnt/β-Catenin signaling to promote functional muscle regeneration in VML.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Volumetric muscle loss (VML) overwhelms the endogenous regenerative capacity of skeletal muscle, leading to serious fibrosis, which further reduces muscle strength and severely affects patients' quality of life. While decellularized extracellular matrix (dECM) scaffolds offer tissue-specific biochemical cues for muscle regeneration, conventional decellularization protocols deplete critical glycosaminoglycans (GAGs), particularly chondroitin sulfate (CS), which are essential for growth factor sequestration and signaling pathway activation. Here, we developed injectable CS-glycosylated dECM microgels via microfluidic technology to restore GAG functionality to promote comprehensive muscle regeneration. We demonstrate that CS functionalization enhances myoblast adhesion, proliferation, migration, and differentiation in vitro. RNA sequencing analysis reveals that CS-mediated enhancement operates principally through activation of canonical Wnt/β-catenin signaling, with coordinated upregulation of downstream myogenic programs. In a rat tibialis anterior VML model, administration with high-CS formulations (H-CS@ECM) greatly promote muscle regeneration, function recovery and vascularization, with the muscle exhibiting enhanced-, blood perfusion, neuromuscular connectivity, and contractile protein expression at 8 weeks. Our findings suggest that CS-glycosylated dECM microgels possess significant translational potential as a minimally invasive and pro-regenerative implant material for VML repair. More broadly, this work establishes GAG modification as a generalizable design principle for enhancing dECM scaffold performance across diverse endogenous tissue regeneration applications, without the addition of exogenous growth factors, cytokines or drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.